GB9501178D0
(en)
*
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Guanine derivative
|
DE69726255T2
(de)
*
|
1996-01-19 |
2004-08-26 |
Glaxo Group Ltd., Greenford |
Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
|
IT1283447B1
(it)
*
|
1996-07-18 |
1998-04-21 |
Ind Chimica Srl |
Processo di preparazione del valaciclovir e relativi intermedi
|
KR20000070223A
(ko)
*
|
1997-01-17 |
2000-11-25 |
에가시라 구니오 |
신규한 z-발라사이클로비르 결정
|
GB0010446D0
(en)
*
|
2000-04-28 |
2000-06-14 |
Glaxo Wellcome Kk |
Pharmaceutical formulation
|
PT1368349E
(pt)
*
|
2001-02-24 |
2007-04-30 |
Boehringer Ingelheim Pharma |
Derivados de xantina, sua preparação e sua utilização como medicamento
|
SK1592004A3
(sk)
*
|
2001-09-07 |
2005-03-04 |
Teva Pharmaceutical Industries Ltd. |
Kryštalické formy valaciklovírus hydrochlóridu
|
EP1453834A1
(en)
*
|
2001-11-05 |
2004-09-08 |
Glaxo Group Limited |
Anhydrous crystal form of valaciclovir hydrochloride
|
HRP20040511A2
(en)
*
|
2001-11-14 |
2004-10-31 |
Teva Pharma |
Synthesis and purification of valacyclovir
|
AU2003240213A1
(en)
*
|
2002-06-24 |
2004-01-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US20050043329A1
(en)
*
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
US20050059684A1
(en)
*
|
2002-10-16 |
2005-03-17 |
Ben-Zion Dolitzky |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
DE60307494D1
(de)
*
|
2002-10-16 |
2006-09-21 |
Teva Pharma |
Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
|
WO2004052892A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Texcontor Etablissement |
Anhydrous crystalline form of valacyclovir hydrochloride
|
AU2003232719A1
(en)
*
|
2003-05-30 |
2005-01-21 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Novel crystalline forms of valacyclovir hydrochloride
|
WO2005000850A2
(en)
*
|
2003-06-02 |
2005-01-06 |
Teva Pharmaceutical Industries, Ltd. |
Novel crystalline forms of valacyclovir hydrochloride
|
US20050192296A1
(en)
*
|
2004-01-21 |
2005-09-01 |
Zvi Harel |
Process for the preparation of valacyclovir hydrochloride
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
EP1761535A1
(en)
*
|
2004-06-30 |
2007-03-14 |
Teva Pharmaceutical Industries Ltd |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US20060178512A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Cheruthur Govindan |
Method for preparing amino acid esters of nucleoside analogues
|
WO2006127217A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Eli Lilly And Company |
Cyclopropanecarboxylate esters of acyclovir
|
EP1746098A1
(en)
|
2005-07-21 |
2007-01-24 |
SOLMAG S.p.A. |
Valacyclovir polymorphs and a process for the preparation thereof
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20070112193A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Khunt Mayur D |
Valacyclovir process
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
PE20110235A1
(es)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CN1903854B
(zh)
*
|
2006-08-09 |
2012-05-23 |
丽珠医药集团股份有限公司 |
一种合成盐酸伐昔洛韦的方法
|
US20080167325A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Bs Praveen Kumar |
Valacyclovir compositions
|
US20080281099A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Mayur Devjibhai Khunt |
Process for purifying valacyclovir hydrochloride and intermediates thereof
|
GB0710277D0
(en)
*
|
2007-05-30 |
2007-07-11 |
Univ Birmingham |
Use of antivirals in the treatment of medical disorders
|
ES2733348T3
(es)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
|
JPWO2009031576A1
(ja)
*
|
2007-09-03 |
2010-12-16 |
味の素株式会社 |
バラシクロビル塩酸塩結晶の製造方法
|
US20090076039A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched valacyclovir
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
EP2326326B1
(en)
*
|
2008-08-15 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
|
WO2010029089A2
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
EP2504002B1
(en)
|
2009-11-27 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
PT2566469T
(pt)
|
2010-05-05 |
2023-01-10 |
Boehringer Ingelheim Int |
Terapia de combinação
|
WO2011158252A1
(en)
|
2010-06-15 |
2011-12-22 |
Matrix Laboratories Ltd |
Process for the preparation of valacyclovir hydrochloride polymorphic form ii
|
JP5843855B2
(ja)
|
2010-06-24 |
2016-01-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病療法
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
CN102584825B
(zh)
*
|
2011-01-17 |
2014-04-02 |
四川科伦药物研究有限公司 |
一种合成盐酸伐昔洛韦的方法
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
WO2013076688A1
(en)
*
|
2011-11-25 |
2013-05-30 |
Piramal Enterprises Limited |
A process for the preparation of valacyclovir hydrochloride
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
EP2849754B1
(en)
|
2012-05-14 |
2022-09-14 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2015128453A1
(en)
|
2014-02-28 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Medical use of a dpp-4 inhibitor
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
CN110437231B
(zh)
*
|
2019-09-04 |
2022-04-29 |
上药康丽(常州)药业有限公司 |
一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|